secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001654954-25-010510
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics expands levosimendan license to exclusive worldwide oral rights; gains manufacturing rights
--------------------------------------------------------------------------------

- Amendment with Orion grants Tenax exclusive worldwide rights to develop, commercialize, and manufacture oral levosimendan products.
- Tenax also obtains manufacturing rights for subcutaneously administered levosimendan products under the expanded license.
- Orion will supply levosimendan API at low triple-digit thousand Euros/kg, minimum order [***] grams, payment within 45 days.
- Fifth Amendment builds on prior agreements; effective September 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495425010510/0001654954-25-010510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495425010510/tennx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-010510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer